首页> 外文会议>Annual International Vicenza Course on Hemodialysis >From Wearable UBtraf iltration Dewlce to Wearable Artificial Kiinef
【24h】

From Wearable UBtraf iltration Dewlce to Wearable Artificial Kiinef

机译:从可穿戴的超滤装置到可穿戴人工kiinef

获取原文

摘要

Introduction: Since the inception of hemodialysis as a treatment for patients with chronic kidney disease, there have been designs created for portable, wearable or implantable devices to improve both quality of therapy delivered and patient quality of life. Methods: We conducted a pilot proof-of-concept study in 8 stable adult hemodialysis patients using a wearable hemodialysis device with a sorbent-based regeneration dialysate system. Results: All patients were safely treated for 4-8 h. Ultrafiltration was successfully performed without any cardiovascular effects, with a reduction in extracellular fluid to total body fluid ratio (from 0.339 +- 0.003 to 0.335 +- 0.003 after treatment; p = 0.002). Respective clearances (ml/min) were: 22.6 +- 1.8 for urea, 20.7 +- 1.8 for creatinine, 21.7 +-1.8 for phosphate and 11.6 +- 1.8 for beta_2-microglobulin. Although the small solute clearances are much lower than for conventional intermittent hemodialysis, this device has been designed to operate for sustained periods, and therefore would be predicted to have equivalent small solute clearances to continuous dialysis treatments (CRRT) in the intensive setting. Safety mechanisms were shown to operate promptly in a case of a venous needle disconnection, and in cases of circuit clotting. ConcIusion:This was a pilot study designed to demonstrate the safety of a wearable hemodialysis device, in addition to confirming safety, we were able to confirm that the device not only had similar clearances to CRRT used in the intensive-care setting, but also increased clearances of middle molecules, such as beta_2-microglobulin and phosphate.
机译:简介:由于血液透析的开始作为治疗慢性肾脏疾病,已设计为便携式,可穿戴或植入设备创建,提高生活治疗交付和患者生存质量都素质。方法:我们进行了8名成人稳定血液透析患者的试验证明了概念研究使用可穿戴式血液透析设备与基于吸附剂的再生透析系统。结果:所有患者均安全地4-8 h后。超滤没有任何心血管效应成功地执行,并在细胞外液的减少,以总体液比(从0.339 + - 0.003〜0.335 + - 0.003处理后; P = 0.002)。各自的间隙(毫升/分钟)分别为:22.6 + - 1.8尿素,20.7 + - 1.8肌酐,21.7 + -1.8磷酸盐和11.6 + - 1.8 beta_2微球蛋白。尽管小分子溶质的间隙比常规间歇性血液透析低得多,这种装置已被设计为持续周期操作,并且因此将被预测为具有等效小溶质的间隙,以在密集设置连续透析治疗(CRRT)。安全机制被证明在静脉针头断开的情况下迅速地操作,并且在电路凝血的情况下。 ConcIusion:这是一个试验性研究,旨在展示可穿戴的血液透析装置的安全性,除了确认安全,我们能够确认该设备不仅有相似的间隙,以CRRT在重症监护环境中使用,而且还增加中间分子,如beta_2 - 微球蛋白和磷酸盐的间隙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号